Immunovant, Inc. Common Stock
IMVTImmunovant, Inc. is a biotechnology company focused on developing and commercializing therapies for autoimmune diseases and other immune-mediated disorders. The company primarily targets B-cell mediated conditions, aiming to provide innovative treatments through its antibody modulation platform.
Company News
Roivant Sciences purchased 16.7 million shares of Immunovant for $350 million, increasing its ownership to 64.65% of outstanding shares. The biotech company focuses on monoclonal antibody therapies for autoimmune diseases and is currently in clinical trials for its lead drug candidate.
Law firm Kahn Swick & Foti, LLC has initiated an investigation into Century Aluminum Company, examining potential breaches of fiduciary duties or violations of state/federal laws by its officers and directors.
Immunovant's stock gained 11% after reporting positive results from a proof-of-concept study for batoclimab, an investigational drug targeting Grave's disease. The study showed 17 out of 21 patients maintained normal thyroid function six months after treatment.
Immunovant presented promising six-month off-treatment data for batoclimab in Graves' disease, showing ~80% of patients maintained normal thyroid function and ~50% achieved anti-thyroid drug-free remission.
Immunovant reported a widened net loss of $0.71 per share in Q1 FY2026, with increased research and development expenses of $101.2 million as the company advanced clinical trials for its lead anti-neonatal Fc receptor antibody IMVT-1402 across six different studies.
